Category: AbbVie

Shedding Light on BIA-ALCL Risks

In a society that celebrates individuality and self-expression, the journey to aesthetics takes many forms. One such road, taken by countless women seeking empowerment and confidence, is breast augmentation. This blog dives deep into the dark and flip side of breast augmentation- Allergan breast implant lawsuits. Before answering the query…

Continue Reading Shedding Light on BIA-ALCL Risks

what will therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a declining cancer death rate – by 33% to be precise – since the…

Continue Reading what will therapy look like in 2034?

Top antibody-drug conjugate (ADC) companies leading the industry

The antibody-drug conjugate (ADC) field is witnessing an expansion in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms of action. Investments in ADC research continue to grow, with significant funding rounds and acquisitions. For example, Novo Holdings’ $105…

Continue Reading Top antibody-drug conjugate (ADC) companies leading the industry

Ten NK cell therapy companies to look out for this year

Natural killer (NK) cells are white blood cells that are a part of the body’s defense mechanism. These cells are on the lookout for any kind of disruption in the immune system, and can kill diseased cells like tumor cells. NK cells are being used in clinical applications to treat…

Continue Reading Ten NK cell therapy companies to look out for this year

Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Continue Reading Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer | Oncology | JAMA Network Open

Achievements, accolades highlight past year at VUMC | VUMC Reporter

  Editor’s note — the following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2023.   Whole-genome sequencing agreement Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies,…

Continue Reading Achievements, accolades highlight past year at VUMC | VUMC Reporter

Advances in Anti-CD20 Therapies for Relapsed or Refractory Large B-Cell Lymphoma From ASH 2023

1. FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma. News release. US Food and Drug Administration. June 21, 2023. Accessed December 6, 2023. www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b 2. FDA grants accelerated approval to glofitamab-gxbm for selected relapsed or refractory large B-cell…

Continue Reading Advances in Anti-CD20 Therapies for Relapsed or Refractory Large B-Cell Lymphoma From ASH 2023

ASH 2023: Lymphoma Studies May Inform Practice

Studies presented at the ASH Annual Meeting 2023 provided new insights and updates that may inform the treatment of lymphomas. Results from the phase 3 SYMPATICO trial showed that adding venetoclax to ibrutinib can improve progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL).1 These results…

Continue Reading ASH 2023: Lymphoma Studies May Inform Practice

Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight’s “Non-Hodgkin lymphoma Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the NHL, historical and forecasted epidemiology as well as the Non-Hodgkin lymphoma market trends in the United States EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. {Delhi, India} To…

Continue Reading Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

The scenario for the biotech industry in 2024 looks upbeat after a challenging ride in 2023. New drug approvals, pipeline development, and an increase in mergers & acquisitions (M&A) activity boosted investor sentiment in the last couple of months, even though an uncertain macroeconomic environment was a headwind. Pharma and…

Continue Reading 3 Biotech Stocks Most Wall Street Analysts Are Bullish About

Ubrogepant Administration in Prodromal Phase Helps Reduce Migraine Attacks

Ubrogepant is well-tolerated and effective for the treatment of a migraine attack when taken during the prodromal phase, according to study findings published in the journal The Lancet. Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for the treatment of acute migraine. To evaluate…

Continue Reading Ubrogepant Administration in Prodromal Phase Helps Reduce Migraine Attacks

Growth Is Still a Better Choice

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is a leader in the global cystic fibrosis therapeutics market. In addition, the company has an extensive portfolio of experimental medicines aimed at treating common diseases such as type 1 diabetes, sickle cell anemia and APOL1-mediated kidney disease (AMKD). Investment thesis On Dec. 8, the Food…

Continue Reading Growth Is Still a Better Choice

Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Hodgkin Lymphoma Pipeline report…

Continue Reading Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

Complete Interim Response, SCT Beats CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Complete Interim Response, SCT Beats CAR T

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13…

Continue Reading Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Reproxalap in Patients with Seasonal Allergic Conjunctivitis

Introduction Reproxalap, a novel chemical entity in late-stage clinical development for the treatment of ocular inflammation, chemically sequesters a class of small molecules known as reactive aldehyde species (RASP). Via covalent binding to amine and thiol residues, RASP modulate the structure and function of proteins in an analog manner1 depending…

Continue Reading Reproxalap in Patients with Seasonal Allergic Conjunctivitis

Measurable Residual Disease-Guided Therapy Promising in CLL

SAN DIEGO — In untreated chronic lymphocytic leukemia (CLL), patients who received ibrutinib plus venetoclax for a duration determined by disease characteristics rather than a fixed schedule had significantly better progression-free and overall survival compared with conventional chemoimmunotherapy, a new phase 3 analysis shows. The targeted therapy combination was also…

Continue Reading Measurable Residual Disease-Guided Therapy Promising in CLL

Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share, Value and Report 2023-2030

The forecasted growth in the treatment of Diffuse Large B-cell Lymphoma (DLBCL) is driven by the increasing preference for targeted therapies. Targeted therapies, such as monoclonal antibodies and kinase inhibitors, offer a less toxic alternative to chemotherapy by focusing on specific molecular targets associated with cancer. Notable examples include rituximab…

Continue Reading Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share, Value and Report 2023-2030

Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

Patients with relapsed diffuse large B cell lymphoma (DLBCL) who achieve a complete remission from interim chemotherapy while awaiting secondary chimeric antigen receptor (CAR) T cell therapy show significantly better outcomes if they then receive conventional autologous stem cell transplantation (auto-HCT), compared with CAR T therapy. “In patients with relapsed…

Continue Reading Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

New data for Roche’s Columvi and Lunsumio presented at ASH

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023…

Continue Reading New data for Roche’s Columvi and Lunsumio presented at ASH

New Data Presented at ASH from the Phase 3 GLOW Study Show

Additional data from the Phase 2 CAPTIVATE study, show 82 percent of patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with fixed-duration ibrutinib plus venetoclax did not need next-line treatment at 54 months1,2 BEERSE, BELGIUM, Dec. 11, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of Johnson & Johnson…

Continue Reading New Data Presented at ASH from the Phase 3 GLOW Study Show

Scientist I, QTAS – Bioinformatics job with AbbVie

AbbVie is seeking a highly motivated scientist to join our Quantitative, Translation & ADME Sciences (QTAS) team in South San Francisco. The ideal candidate will have a strong background in immuno-oncology, bioinformatics and data science, ability to drive cutting-edge science and work a matrix environment. Applicants having experience in R and…

Continue Reading Scientist I, QTAS – Bioinformatics job with AbbVie

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Continue Reading Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

Up-front treatment with the combination of navitoclax and ruxolitinib (Jakafi) significantly reduced spleen volume by 35% or more at week 24 (SVR35W24) compared with ruxolitinib plus placebo for patients with myelofibrosis; however, a significant difference was not observed in total symptom score (TSS) version 4.0 between the arms, according to…

Continue Reading Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun

As a business journalism publication, BioSpace doesn’t get many news days like we had on Friday. Not just one but two major FDA approvals happened simultaneously for the first cell-based gene therapies to treat patients with sickle cell disease.    While the FDA’s decision regarding Vertex Pharmaceuticals and CRISPR Therapeutics’…

Continue Reading Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun

CRISPR with Casgevy, Atlas Venture, etc

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the much-awaited CRISPR-based drug Casgevy, discuss the new Gavi initiative that plans to dramatically ramp up vaccine manufacturing in Africa, and more. Have a nice…

Continue Reading CRISPR with Casgevy, Atlas Venture, etc

B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the B-Cell Lymphomas pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphomas pipeline therapeutics…

Continue Reading B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Ubrogepant Taken During Migraine Prodrome Reduces Headache Severity: Phase 3 Clinical Trial

Full findings from the phase 3 PRODROME study (NCT04492020) of ubrogepant (Ubrelvy; AbbVie) have been announced and published in The Lancet, demonstrating a positive impact of the oral calcitonin gene-related peptide inhibitor on migraine symptoms during the prodrome phase, according to a statement from the manufacturer.1 David W Dodick, MD…

Continue Reading Ubrogepant Taken During Migraine Prodrome Reduces Headache Severity: Phase 3 Clinical Trial

Blau syndrome Market Scope and overview

Blau syndrome Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report provides an overview including definitions, applications, product launches, developments, challenges, and regions. It is predicted that the market will show strong development due to the driven consumption in various…

Continue Reading Blau syndrome Market Scope and overview

FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis

According to a recent announcement, the FDA has placed a clinical hold on the development program for fenebrutinib (Roche), an investigational oral, reversible, and noncovalent Bruton tyrosine kinase (BTK) inhibitor in development for patients with multiple sclerosis (MS).1 The decision was based on 2 recent cases of hepatic transaminase elevations…

Continue Reading FDA Places Clinical Hold on Roche’s BTK Inhibitor Fenebrutinib for Multiple Sclerosis

Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Joyce O’Shaughnessy, MD The addition of pembrolizumab (Keytruda) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses (pCRs) in patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer, including subsets defined by geography, stage, baseline clinical lymph node involvement, and PD-L1 expression, according to data…

Continue Reading Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Tickets, Fri, Dec 8, 2023 at 3:00 PM

Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Attend In-Person or Virtually for an exciting and informative event, Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care, happening at the San Diego Convention Center on Friday, December 8, 2023, 3:00…

Continue Reading Hybrid Friday Satellite Symposium on R/R DLBCL | Preceding the 65th ASH Annual Meeting & Exposition Tickets, Fri, Dec 8, 2023 at 3:00 PM

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

Abstract A major unmet need in the cystic fibrosis (CF) therapeutic landscape is the lack of effective treatments for nonsense CFTR mutations, which affect approximately 10% of CF patients. Correction of nonsense CFTR mutations via genomic editing represents a promising therapeutic approach. In this study, we tested whether prime editing,…

Continue Reading Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells

MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis (MOR)

tonaquatic Thesis overview MorphoSys AG (NASDAQ:MOR) recently announced positive topline results from its phase 3 trial of pelabresib in myelofibrosis (MF). The study easily met the primary endpoint. However, despite the strong positive trend, statistical significance was not achieved at key secondary endpoints assessing symptomatic improvement. Nevertheless, in a pre-specified…

Continue Reading MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis (MOR)

Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

As per the report by Fortune Business Insights, The Biopharmaceuticals Market size is projected to reach USD 799.76 Billion by 2030, at a CAGR of 7.9% during the forecast period. Biopharmaceuticals Market Biopharmaceuticals Market (2023-2030) Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) — The global biopharmaceuticals market size was USD…

Continue Reading Biopharmaceuticals Market Size to Surpass USD 799.76 Billion by 2030, at a CAGR of 7.9%

Follicular Lymphoma Drug Co-Developed by AbbVie and Genmab Gets FDA Breakthrough Designation

AbbVie and Genmab will share commercial responsibilities in the United States and Japan for epcoritamab-bysp (Epkinly), whereas AbbVie will be responsible for further global commercialization. The FDA has granted Breakthrough Therapy Designation to epcoritamab-bysp (Epkinly; AbbVie and Genmab) for the treatment of adults with follicular lymphoma (FL) that is relapsed…

Continue Reading Follicular Lymphoma Drug Co-Developed by AbbVie and Genmab Gets FDA Breakthrough Designation

BCL-2-Like Protein Market Will Generate Record Revenue by 2029

BCL-2-Like Protein Market is anticipated to grow at a significant CAGR during the forecast period. BCL-2, also known as B Cell Lymphoma 2, is a protein encoding gene belonging to the B cell lymphoma family. The market growth is majorly attributable to the growth is the significant prevalence of diffuse…

Continue Reading BCL-2-Like Protein Market Will Generate Record Revenue by 2029

Phase 3 Trials Reveal New Standards of Care for NSCLC

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

Continue Reading Phase 3 Trials Reveal New Standards of Care for NSCLC

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

Medical Aesthetics Market Size Worth USD 43.2 Billion in

Vancouver, Nov. 22, 2023 (GLOBE NEWSWIRE) — The global medical aesthetics market size was USD 15.3 Billion in 2022 and is expected to register rapid revenue CAGR of 11.0% during the forecast period. Key factors propelling this growth include the increasing awareness of aesthetic procedures, a surge in the adoption…

Continue Reading Medical Aesthetics Market Size Worth USD 43.2 Billion in

Phase 3 Study for AbbVie’s Ubrelvy Reports Promising Results

Medication focuses on the acute treatment of migraines. AbbVie announced results published in The Lancet evaluating the efficacy, safety, and tolerability of Ubrelvy (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome of a migraine attack. According to a Phase 3 prodrome study, results indicated…

Continue Reading Phase 3 Study for AbbVie’s Ubrelvy Reports Promising Results

Senior Scientist, Bioinformatics II job with AbbVie

AbbVie’s Genomics Research Center Computational Genomics is looking for a highly motivated computational biologist (Senior Scientist II, Bioinformatics) to join a team of bioinformatics scientists investigating aging and age-related diseases. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, and human genetics. The GRC works across all R&D…

Continue Reading Senior Scientist, Bioinformatics II job with AbbVie

Sr Scientist I, Bioinformatics Engineer job with AbbVie

The Genomics Research Center (GRC) is a center of excellence for genetics and genomics that supports both Discovery and Development. The GRC plays an integral role towards our goal of developing extraordinary genetics and genomics research, focusing on finding the right targets and helping us better understand not only human…

Continue Reading Sr Scientist I, Bioinformatics Engineer job with AbbVie

Phase 3 PRODROME Study Highlights Ubrogepant’s Impact on Migraine Prior to Attacks

After the initial data was presented earlier this year, investigators have published full findings of the phase 3 PRODROME study (NCT04492020) demonstrating ubrogepant’s (Ubrelvy; AbbVie) positive impact on migraine during the prodrome phase in The Lancet. Led by David W. Dodick, MD, professor of neurology at Mayo Clinic Scottsdale, PRODROME…

Continue Reading Phase 3 PRODROME Study Highlights Ubrogepant’s Impact on Migraine Prior to Attacks

The coming AI-enabled pharma revolution

In today’s challenging economic climate, every company is tasked with achieving more with limited resources. During this timely roundtable discussion, The Coming AI-Enabled Pharma Revolution, sponsored by Boundless Life Sciences Group, industry leaders explored the transformative potential of AI to enhance clinical and commercial processes, boost productivity, maximize ROI and…

Continue Reading The coming AI-enabled pharma revolution

Landmark academic-industry partnership harvests human genome “fruits” for research – Nashville Medical News

  By Bill Snyder   The first fruits of a landmark academic-industry partnership that is harvesting the depth and breadth of the human genome to better understand and treat disease will become available to researchers in the spring of 2024. Underway is whole genome sequencing of DNA samples from approximately…

Continue Reading Landmark academic-industry partnership harvests human genome “fruits” for research – Nashville Medical News

Landmark academic-industry partnership harvests human genome “fruits” for research | VUMC Reporter

  by Bill Snyder The first fruits of a landmark academic-industry partnership that is harvesting the depth and breadth of the human genome to better understand and treat disease will become available to researchers in the spring of 2024. Underway is whole genome sequencing of DNA samples from approximately 35,000…

Continue Reading Landmark academic-industry partnership harvests human genome “fruits” for research | VUMC Reporter

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Continue Reading Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Continue Reading Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Your weekly fix of the latest biotech news: November 10, 2023

You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under…

Continue Reading Your weekly fix of the latest biotech news: November 10, 2023

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Key Points Question  Is clonal hematopoiesis of indeterminate potential (CHIP) detected at the time of hematopoietic stem transplant (HCT) associated with increased rates of cardiovascular disease (CVD) among patients with multiple myeloma (MM) following HCT? Finding  In this cohort study of patients with MM undergoing HCT, CHIP was highly prevalent…

Continue Reading Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant | Cardiology | JAMA Cardiology

Genmab Announces Financial Results for the First Nine

November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY®) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy Epcoritamab…

Continue Reading Genmab Announces Financial Results for the First Nine

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Genmab A/S Media Release COPENHAGEN, Denmark; November 2, 2023 Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populations Oral presentations highlighting new findings from a clinical trial of epcoritamab in patients with relapsed/refractory (R/R) diffuse large…

Continue Reading Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data | GigaScience

Abstract Low-level mosaic epimutations within the BRCA1 gene promoter occur in 5–8% of healthy individuals and are associated with a significantly elevated risk of breast and ovarian cancer. Similar events may also affect other tumor suppressor genes, potentially being a significant contributor to cancer burden. While this opens a new…

Continue Reading epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data | GigaScience

Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned

Novartis’s $3.2 billion acquisition of Chinook Therapeutics brought two drug prospects for a chronic kidney disorder with few approved treatments. One of these newly acquired drugs has now met the main goal of its Phase 3 test, results the Swiss pharmaceutical said will support plans to seek accelerated FDA approval…

Continue Reading Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned

MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer

Oct 28 2023Reviewed by Lily Ramsey, LLM The conditional Marketing Authorization for Great Britain is based on the single-arm Phase 1/2 EPCORE NHL-1 trial data, which demonstrated a 62% (86/139) overall response rate and 39% (54/139) complete response rate in patients. However, further data are awaited from an ongoing phase…

Continue Reading MHRA grants conditional marketing authorization for AbbVie’s Tepkinly to treat aggressive blood cancer

Lupus Therapeutics, AbbVie team up for upadacitinib Phase 3 trial

Lupus Therapeutics is partnering with AbbVie for the Phase 3 clinical program of upadacitinib for people with systemic lupus erythematosus (SLE). “The partnership with AbbVie will support the accelerated evaluation of upadacitinib as a potential treatment for individuals living with SLE,” Stacie Bell, PhD, Lupus Therapeutics’ executive vice president, said…

Continue Reading Lupus Therapeutics, AbbVie team up for upadacitinib Phase 3 trial

Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

October 26, 2023 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading Phase 3 data confirm rapid efficacy of nemolizumab for atopic dermatitis treatment

ASCO Reading Room | Personalized Upfront Treatments for Rare Lymphomas

As with many cancers, personalized therapy has replaced a one-size-fits-all approach for the frontline management of some nodal peripheral T-cell lymphomas (PTCLs). Although these represent only about 10-15% of all non-Hodgkin lymphomas, they encompass a diverse group with more than 30 different subtypes that share a common derivation from either…

Continue Reading ASCO Reading Room | Personalized Upfront Treatments for Rare Lymphomas

Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network

NEW YORK , Oct. 24, 2023 /PRNewswire/ — Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ ® ) in individuals living with systemic lupus erythematosus (SLE). In this partnership, Lupus Therapeutics will…

Continue Reading Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network

Epcoritamab Receives UK Approval for R/R DLBCL After 2 Prior Lines of Therapy

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted conditional marketing authorization to epcoritamab-bysp (Tepkinly) monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after 2 or more systemic therapy.1,2 The decision was supported by data from the phase 1/2 EPCORE…

Continue Reading Epcoritamab Receives UK Approval for R/R DLBCL After 2 Prior Lines of Therapy

Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines

–All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508).–Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and short duration of effect within 2-3 weeks.–If approved,…

Continue Reading Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines

Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines

(RTTNews) – Allergan Aesthetics, an AbbVie company (ABBV), announced positive results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 studies evaluated the safety and efficacy of BoNT/E versus placebo in a total of…

Continue Reading Allergan Announces Positive Results From Phase 3 Studies Of TrenibotulinumtoxinE In Glabella Lines

Allergan (ABBV) Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 multicenter, randomized, double-blind, placebo-controlled studies evaluated the safety and efficacy of BoNT/E versus…

Continue Reading Allergan (ABBV) Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines

Allergan Announces Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lines

Allergan Aesthetics, an AbbVie company, has announced positive topline results1 of two pivotal phase 3 clinical trials for trenibotulinumtoxinE (BoNT/E). The trials, named M21-500 and M21-508, focused on the treatment of moderate to severe glabellar lines and have shown remarkable promise. The phase 3 trials, carried out across multiple centers,…

Continue Reading Allergan Announces Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lines

Novel injectable bispecific antibody for advanced lymphoma receives EU and UK green light

The injectable bispecific antibody epcoritamab (brand name Tepkinly) has been granted conditional marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), its manufacturer Abbvie has announced. This follows its conditional marketing authorisation by the European Commission in late September 2023. The conditional marketing authorisations recommend epcoritamab as a…

Continue Reading Novel injectable bispecific antibody for advanced lymphoma receives EU and UK green light

Abbvie Set to Announce Q3 2023 Results Amid Robust Immunology Drug Sales By Investing.com

AbbVie (NYSE:) is poised to announce its Q3 2023 results on Thursday, October 27, following a previous quarter that saw an earnings surprise of 4.30%. This announcement comes as the company’s immunology drugs, Skyrizi and Rinvoq, continue to show robust sales performance. Notably, Skyrizi has proven superior over competitors Otezla…

Continue Reading Abbvie Set to Announce Q3 2023 Results Amid Robust Immunology Drug Sales By Investing.com

Scientist or Sr. Scientist, Bioinformatics

The Genomic Research Center Computational Oncology group (GRC-CO) at AbbVie Bay Area is seeking a highly motivated computational biologist to play an integral role in a multi-disciplinary team focused on developing new therapies and approaches for cancer treatment. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, human…

Continue Reading Scientist or Sr. Scientist, Bioinformatics

BioSpace hiring Senior Scientist, Bioinformatics II in North Chicago, Illinois, United States

AbbVie’s Genomics Research Center Computational Genomics is looking for a highly motivated computational biologist (Senior Scientist II, Bioinformatics) to join a team of bioinformatics scientists investigating aging and age-related diseases. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, and human genetics. The GRC works across all R&D…

Continue Reading BioSpace hiring Senior Scientist, Bioinformatics II in North Chicago, Illinois, United States

Senior Scientist, Bioinformatics II

AbbVie’s Genomics Research Center Computational Genomics is looking for a highly motivated computational biologist (Senior Scientist II, Bioinformatics) to join a team of bioinformatics scientists investigating aging and age-related diseases. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, and human genetics. The GRC works across all R&D…

Continue Reading Senior Scientist, Bioinformatics II

BioSpace hiring Scientist, Bioinformatics Engineer in South San Francisco, California, United States

The Genomics Research Center (GRC) is a center of excellence for genetics and genomics that supports both Discovery and Development. The GRC plays an integral role towards our goal of developing extraordinary genetics and genomics research, focusing on finding the right targets and helping us better understand not only human…

Continue Reading BioSpace hiring Scientist, Bioinformatics Engineer in South San Francisco, California, United States

AbbVie’s DLBCL Drug EPKINLY, Crohn’s Disease Drug RINVOQ Get Health Canada Approval

(RTTNews) – AbbVie (ABBV) announced Tuesday that Health Canada has approved EPKINLY (epcoritamab injection/epcoritamab for injection) to treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma or DLBCL, as well as RINVOQ (upadacitinib) to treat moderately to severely active Crohn’s Disease. EPKINLY has received the authorization with conditions as the first…

Continue Reading AbbVie’s DLBCL Drug EPKINLY, Crohn’s Disease Drug RINVOQ Get Health Canada Approval

Latest Phase 3 Trial Data Announced for Upadacitinib Treatment of Atopic Dermatitis

Jonathan Silverberg, MD Credit: gwdocs.com The drug upadacitinib may be safe and effective long-term in treating patients with moderate-to-severe atopic dermatitis (AD) across 140 weeks, according to new data presented at the 32nd European Academy of Dermatology and Venereology (EADV) Congress in Berlin.1 These findings, announced by AbbVie from EADV,…

Continue Reading Latest Phase 3 Trial Data Announced for Upadacitinib Treatment of Atopic Dermatitis

Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3

AbbVie recently announced that its phase 2b study investigating upadacitinib (Rinvoq) for the treatment of adults with nonsegmental vitiligo met the primary end point of percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with the 11 mg and 22 mg doses versus placebo….

Continue Reading Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3

AbbVie Advancing Rinvoq to Phase 3 Studies in Vitiligo

By Colin Kellaher AbbVie on Thursday said it is moving its blockbuster immunology drug Rinvoq into Phase 3 studies in vitiligo after a successful Phase 2b study in the chronic skin condition. The North Chicago, Ill., biopharmaceutical company said the Phase 2b study evaluating Rinvoq in adults with non-segmental vitiligo…

Continue Reading AbbVie Advancing Rinvoq to Phase 3 Studies in Vitiligo

Meet a New NSCLC Target: c-MET

© Dr_Microbe – stock.adobe.com Non-small cell lung cancer (NSCLC) is the most common type of lung cancer in the United States, accounting for about 85% of all lung carcinomas. It is the leading cause of cancer death in the U.S. Current treatments include lobectomy (surgery to remove the part of…

Continue Reading Meet a New NSCLC Target: c-MET

DLBCL News Briefs – Page 2 of 10

News Briefs » DLBCL News Briefs » Page 2 MicroRNA Sequencing May Detect DLBCL Biomarker Patterns MicroRNA sequencing can detect specific patterns in patients with diffuse large B-cell lymphoma (DLBCL) that could be used to guide diagnosis and treatment and assess prognosis, according to a recently published study in the journal…

Continue Reading DLBCL News Briefs – Page 2 of 10

AbbVie: Three Ongoing Phase 3 Studies Show Long-term Efficacy Of RINVOQ

(RTTNews) – AbbVie (ABBV) reported new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further showed the long-term efficacy and safety profile of RINVOQ among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks….

Continue Reading AbbVie: Three Ongoing Phase 3 Studies Show Long-term Efficacy Of RINVOQ

AbbVie Says Phase 3 Trials Support Long-Term Efficacy, Safety Profile of Atopic Dermatitis Treatment -October 11, 2023 at 09:41 am EDT

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn’s disease, thyroid disease, Parkinson’s disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany…

Continue Reading AbbVie Says Phase 3 Trials Support Long-Term Efficacy, Safety Profile of Atopic Dermatitis Treatment -October 11, 2023 at 09:41 am EDT

ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…

Continue Reading ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

BioSpace hiring Sr. Scientist I, Bioinformatics in Irvine, CA

The Toxin Innovation Group at AbbVie seeks a highly skilled and motivated bioinformatics scientist (Senior Scientist I, bioinformatics) focused on novel neurotoxin discovery research. The Senior Scientist will play an integral role in our research team, contributing to the generation, analysis and interpretation of genomic data to advance our understanding…

Continue Reading BioSpace hiring Sr. Scientist I, Bioinformatics in Irvine, CA

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Key Points Question  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…

Continue Reading Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology

Phase 3 Trial for Venetoclax for Multiple Myeloma Misses Its Primary End Point

Abnormal plasma cel in multiple myeloma: ©LASZLO – stock. adobe.com The phase 3 CANOVA trial (NCT03539744) testing venetoclax (Venclexta) plus dexamethasone in relapsed or refractory multiple myeloma missed its primary end point of progression-free survival (PFS). Patients who received the venetoclax/dexamethasone combination had a median PFS of 9.9 months compared…

Continue Reading Phase 3 Trial for Venetoclax for Multiple Myeloma Misses Its Primary End Point

Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints

  CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and Adolescents with Congenital Adrenal Hyperplasia Key Secondary Endpoint Demonstrated a Statistically Significant Decrease from Baseline in Daily Glucocorticoid Dose while Maintaining Androgen Control Crinecerfont Was…

Continue Reading Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints

Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Credit: CC0 Public Domain Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to…

Continue Reading Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Phase 3 trial of Venclexta for myeloma misses main goal | But more patients seen to respond to therapy than Pomalyst combo

People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the corticosteroid, according to data from a Phase 3 clinical trial. Results from the trial, dubbed CANOVA (NCT03539744), also showed that the Venclexta combo was associated with a…

Continue Reading Phase 3 trial of Venclexta for myeloma misses main goal | But more patients seen to respond to therapy than Pomalyst combo

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

For Immediate Release Chicago, IL – October 2, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Lilly…

Continue Reading The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class. The US regulator is reviewing odronextamab for two forms of B-cell non-Hodgkin lymphoma (NHL) – follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) – in patients…

Continue Reading FDA starts swift review of Regeneron’s CD20 bispecific

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma | Small Molecules

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma Details Category: Small Molecules Published on Saturday, 30 September 2023 10:46 Hits: 112 CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone …

Continue Reading AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma | Small Molecules

AbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple Myeloma

By Colin Kellaher AbbVie on Friday said a Phase 3 study evaluating the safety and efficacy of its venetoclax cancer drug in combination with dexamethasone missed its key goal in certain patients with the blood cancer multiple myeloma. The North Chicago, Ill., biopharmaceutical company said the combination didn’t show significantly…

Continue Reading AbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple Myeloma

AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the…

Continue Reading AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

Phase 3 Study Shows Promising Results for Venetoclax Combination Therapy in Multiple Myeloma

As of September 29, 2023, AbbVie conducted a Phase 3 study called CANOVA to assess the effectiveness and safety of a combination treatment involving venetoclax and dexamethasone for patients with relapsed or refractory multiple myeloma who have a specific genetic mutation (t(11;14)-positive) and have undergone two or more prior treatments….

Continue Reading Phase 3 Study Shows Promising Results for Venetoclax Combination Therapy in Multiple Myeloma

Biotechnology Market expected to Witness a Sustainable Growth over 2021-2031

PRESS RELEASE Published September 27, 2023 New York, Biotechnology is the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services. Today, biotechnology is being used to create new and improved crop varieties, develop renewable fuels, and create new industrial and…

Continue Reading Biotechnology Market expected to Witness a Sustainable Growth over 2021-2031

AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

Pictured: AbbVie corporate office in Illinois/iStock, vzphotos AbbVie has walked away from its collaboration and license agreement with Caribou Biosciences, the Berkeley-based biotech announced in an SEC filing posted Tuesday.   AbbVie’s decision was a strategic move by the company “and was unrelated to Caribou’s performance under the agreement or…

Continue Reading AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

Caribou Bioscience (CRBU) Announces Termination of Collaboration and License Agreement by AbbVie (ABBV)

On September 26, 2023, Caribou Bioscience, Inc (NASDAQ: CRBU) received notice from AbbVie Manufacturing Management Unlimited Company (NASDAQ: ABBV) that AbbVie has elected to terminate the Collaboration and License Agreement, as amended, by and between the Company and AbbVie, dated February 9, 2021 (the “Agreement”). AbbVie exercised its right to…

Continue Reading Caribou Bioscience (CRBU) Announces Termination of Collaboration and License Agreement by AbbVie (ABBV)

European Commission OKs Epcoritamab for R/R Diffuse Large B-Cell Lymphoma

Epcoritamab was approved by the FDA for relapsed/refractory DLBCL not otherwise specified or arising from indolent lymphoma and high-grade B-cell lymphoma after 2 or more previous lines of therapy in May 2023. The European Commission has granted conditional marketing authorization approval to epcoritamab-bysp (Tepkinly) for the treatment of adult patients…

Continue Reading European Commission OKs Epcoritamab for R/R Diffuse Large B-Cell Lymphoma

AbbVie’s (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

AbbVie ABBV and partner Genmab GMAB announced that the European Commission has granted conditional marketing authorization to epcoritamab for treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). DLBCL is a common, aggressive and fast-growing form of non-Hodgkin’s lymphoma (NHL). Epcoritamab will be marketed as Tepkinly in the European…

Continue Reading AbbVie’s (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

AbbVie on LinkedIn: #lymphoma #dlbcl

Today kicks off #HBCUWeek. Stephanie Pulliam, PhD, MBA, an HBCU alumnus and our marketing manager, new product planning, highlights how her experience at AbbVie has supported her career growth. Are you an #HBCU grad looking for a new role? Join us: bit.ly/3t5jI4G #BelongAtAbbVie [Video description: Stephanie Pulliam, Alabama A&M University…

Continue Reading AbbVie on LinkedIn: #lymphoma #dlbcl

AbbVie gets EC’s nod for Tepkinly to treat relapsed or refractory DLBCL

The conditional approval is based on the results from the EPCORE NHL-1 Phase 1/2 trial in which the DLBCL patients treated with Tepkinly achieved an overall response rate of 62% and a complete response rate of 39% EC clears AbbVie’s Tepkinly. (Credit: AbbVie Inc.) AbbVie has received conditional marketing authorisation…

Continue Reading AbbVie gets EC’s nod for Tepkinly to treat relapsed or refractory DLBCL

Epcoritamab Wins European and Japanese Approval for Select Types of R/R LBCL

The European Commission (EC) has granted conditional marketing authorization to epcoritamab-bysp (Tepkinly) for use as a single agent in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following 2 or more lines of systemic treatment.1 Additionally, Japan’s Ministry of Health, Labour, and Welfare has approved the agent…

Continue Reading Epcoritamab Wins European and Japanese Approval for Select Types of R/R LBCL